Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 13/20 | 0.49 |
| ▸ | STK17B | O94768 | 9/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | BLK | P51451 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13310813 | 0.85 | STK17A (0.57) | STK17ASTK17BAXLKDRCHEK1 | |
| SCHEMBL13348089 | 0.84 | STK17A (0.57) | STK17ASTK17BAXLKDRCSNK2A1 | |
| SCHEMBL3374472 | 0.84 | STK17A (0.47) | STK17ASTK17BAXLKDRCHEK1 | |
| SCHEMBL13310796 | 0.83 | STK17A (0.56) | STK17ASTK17BKDRCHEK1CSNK2A1 | |
| SCHEMBL3345879 | 0.82 | STK17A (0.52) | STK17ASTK17BAXLKDRCHEK1 | |
| SCHEMBL13310789 | 0.82 | STK17A (0.63) | STK17ASTK17B | |
| SCHEMBL3377446 | 0.82 | CSNK2A1 (0.52) | STK17ASTK17BKDRCSNK2A1BCL6 | |
| SCHEMBL13310787 | 0.81 | STK17A (0.55) | STK17ASTK17BAXLCHEK1CSNK2A1 | |
| SCHEMBL3375863 | 0.80 | STK17A (0.54) | STK17ASTK17BAXLCSNK2A1BCL6 | |
| SCHEMBL3376119 | 0.80 | STK17A (0.52) | STK17ASTK17BKDRCHEK1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | STK17A 1984/4885STK17B 2457/4885AXL 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.